Literature DB >> 17375278

[High-dose chemotherapy and hematopoietic stem cell transplantation in patients with germ cell cancer].

L Weissbach1, J Beyer.   

Abstract

In cases of germ cell tumors, urologists cooperate with oncologists to determine the best timing for high-dose chemotherapy (HDC). In the primary treatment of patients with"intermediate" and"poor" prognosis, HDC conveys no benefit. These patients are treated with four cycles of cisplatin, etoposide, and bleomycin (BEP). After failure of the standard therapy again four cycles of conventional-dose combination chemotherapy are necessary in good prognosis patients: cisplatin, ifosfamide and either etoposide (VIP or PEI), vinblastine (VeIP) or paclitaxel (TIP). HDC should be considered in patients who fail primary treatment, and who show unfavorable prognostic features prior to salvage treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17375278     DOI: 10.1007/s00120-007-1318-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  9 in total

Review 1.  [Chemotherapy for germ cell cancer].

Authors:  J Beyer; C Bokemeyer
Journal:  Urologe A       Date:  2004-12       Impact factor: 0.639

2.  A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours.

Authors:  J-L Pico; G Rosti; A Kramar; H Wandt; V Koza; R Salvioni; C Theodore; G Lelli; W Siegert; A Horwich; M Marangolo; W Linkesch; G Pizzocaro; H-J Schmoll; J Bouzy; J-P Droz; P Biron
Journal:  Ann Oncol       Date:  2005-05-31       Impact factor: 32.976

3.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.

Authors:  R J Motzer; M Mazumdar; J Sheinfeld; D F Bajorin; H A Macapinlac; M Bains; L Reich; C Flombaum; T Mariani; W P Tong; G J Bosl
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

Review 5.  European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).

Authors:  H J Schmoll; R Souchon; S Krege; P Albers; J Beyer; C Kollmannsberger; S D Fossa; N E Skakkebaek; R de Wit; K Fizazi; J P Droz; G Pizzocaro; G Daugaard; P H M de Mulder; A Horwich; T Oliver; R Huddart; G Rosti; L Paz Ares; O Pont; J T Hartmann; N Aass; F Algaba; M Bamberg; I Bodrogi; C Bokemeyer; J Classen; S Clemm; S Culine; M de Wit; H G Derigs; K P Dieckmann; M Flasshove; X Garcia del Muro; A Gerl; J R Germa-Lluch; M Hartmann; A Heidenreich; W Hoeltl; J Joffe; W Jones; G Kaiser; O Klepp; S Kliesch; L Kisbenedek; K U Koehrmann; M Kuczyk; M P Laguna; O Leiva; V Loy; M D Mason; G M Mead; R P Mueller; N Nicolai; G O N Oosterhof; T Pottek; O Rick; H Schmidberger; F Sedlmayer; W Siegert; U Studer; S Tjulandin; H von der Maase; P Walz; S Weinknecht; L Weissbach; E Winter; C Wittekind
Journal:  Ann Oncol       Date:  2004-09       Impact factor: 32.976

6.  Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.

Authors:  H-J Schmoll; C Kollmannsberger; B Metzner; J T Hartmann; N Schleucher; P Schöffski; J Schleicher; O Rick; J Beyer; D Hossfeld; L Kanz; W E Berdel; R Andreesen; C Bokemeyer
Journal:  J Clin Oncol       Date:  2003-10-20       Impact factor: 44.544

7.  Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables.

Authors:  Daniel A Vaena; Rafat Abonour; Lawrence H Einhorn
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544

8.  Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.

Authors:  P J Loehrer; R Gonin; C R Nichols; T Weathers; L H Einhorn
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

9.  Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.

Authors:  Anja Lorch; Christian Kollmannsberger; Joerg Thomas Hartmann; Bernd Metzner; Ingo G H Schmidt-Wolf; Wolfgang E Berdel; Florian Weissinger; Jan Schleicher; Gerlinde Egerer; Antje Haas; Rebekka Schirren; Jörg Beyer; Carsten Bokemeyer; Oliver Rick
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544

  9 in total
  1 in total

1.  Semi-mechanistic model for neutropenia after high dose of chemotherapy in breast cancer patients.

Authors:  Amelia Ramon-Lopez; Ricardo Nalda-Molina; Belen Valenzuela; Juan Jose Perez-Ruixo
Journal:  Pharm Res       Date:  2009-06-02       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.